Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Total Liabilities (2017 - 2025)

Dianthus Therapeutics has reported Total Liabilities over the past 8 years, most recently at $31.0 million for Q3 2025.

  • Quarterly results put Total Liabilities at $31.0 million for Q3 2025, up 89.55% from a year ago — trailing twelve months through Sep 2025 was $31.0 million (up 89.55% YoY), and the annual figure for FY2024 was $21.5 million, up 104.38%.
  • Total Liabilities for Q3 2025 was $31.0 million at Dianthus Therapeutics, up from $23.0 million in the prior quarter.
  • Over the last five years, Total Liabilities for DNTH hit a ceiling of $202.6 million in Q2 2022 and a floor of $4.0 million in Q2 2023.
  • Median Total Liabilities over the past 4 years was $16.3 million (2024), compared with a mean of $30.8 million.
  • Biggest five-year swings in Total Liabilities: crashed 98.01% in 2023 and later skyrocketed 166.26% in 2024.
  • Dianthus Therapeutics' Total Liabilities stood at $9.5 million in 2022, then rose by 11.43% to $10.5 million in 2023, then surged by 104.38% to $21.5 million in 2024, then skyrocketed by 43.94% to $31.0 million in 2025.
  • The last three reported values for Total Liabilities were $31.0 million (Q3 2025), $23.0 million (Q2 2025), and $20.0 million (Q1 2025) per Business Quant data.